Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

jor programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (http://www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

* the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

* the safety and efficacy of the Company's products or product candidates;

* the Company's assessment of its clinical trials;

* the commencement and completion of clinical trials;

* the Company's ability to develop, manufacture, license and sell its

products or product candidates;

* the Company's ability to enter into and successfully execute license and

collaborative agreements, if any;

* the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  A recent study by Feucht ... compared the Arthrosurface HemiCAP® Wave implant, which is ... "onlay" design implant for isolated patellofemoral disease. While ... and pain scores, none of the patients in ... However, 53% of the patients in the "onlay" ...
(Date:8/27/2015)... Calif. , Aug. 27, 2015 ... milestone in the commercial development of the company,s ... The Smart Oxygen device, being developed by ieCrowd,s ... to a patient,s changing demand for oxygen based ... the 510 (k) submission for the Smart Oxygen ...
(Date:8/27/2015)... MEETING, Pa. , Aug. 27, 2015  Now ... decommissioning the Da Vinci S™ surgical robot, hospitals with ... replacement plans. They also need to see where they ... procedures on the right patients? Have they adopted best ... robotic surgery program in the future? ECRI ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 2ECRI Institute's New Robotic Surgery Service Helps Hospitals Brace for Change 3
... In the year since a devastating earthquake struck Haiti on ... world have launched and supported projects to help the country ... began, Rotary clubs started a $200,000 initiative to implement cholera ... waterborne disease. Rotary clubs worldwide have contributed more ...
... Cardinal Health plans to release second-quarter financial results for its ... of trading on the New York Stock Exchange. ... Feb. 3 at 8:30 a.m. EST to discuss second-quarter results. ... the Investor page at cardinalhealth.com/investors or dial 857-350-1669 passcode 24786608. ...
Cached Medicine Technology:Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 2Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 3Cardinal Health to Release Second-Quarter Results on Feb. 3 2
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ) ... Communications Director for InHealth Media. Mr. Spector comes with a wide array ... doing on-air television, producing shows, on air-radio and media relations. , Brian ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been ... Place, N.Y. "I specialize in manual therapy, and my invention will provide headache ... used for additional muscle dysfunction throughout the body." , They developed THE RELIEVER ...
(Date:8/29/2015)... ... ... Next weekend is Labor Day weekend, the last bash of the season ... year). For IT security personnel, it should also mark the perfect time to make ... than a simple headache. , Joe Caruso, founder and CEO-CTO of Global Digital ...
(Date:8/29/2015)... TX (PRWEB) , ... August 29, 2015 , ... ... allows the company to freely market and sell Arterosil and Arterosil HP, and ... Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... Inc.,(Nasdaq: CVTX ) announced today that Ranexa(R) ... primary composite endpoint of CV,death, myocardial infarction or ... 1,935 patients with an elevated (>80pg/ml) level of ... (p=0.009). The data were presented today by ...
... Inc., the leading,provider of Web-based employee performance and ... 2007 was the organization,s strongest,to date. The organization ... percent year-over-year revenue growth over the third quarter ... high priority for our,organization and this new solution ...
... Introduced in U.S., LAWRENCE, Kan., and ... system, a proprietary meat identification and traceability,system ... by the United States,Department of Agriculture,s (USDA) ... (PVP). The DNA TraceBack system enables retailers,meat ...
... for high blood pressure return to normal pressure levels ... summer, Veterans Affairs (VA) researchers reported at the American ... electronic health records from 15 VA hospitals in warmer ... identified 443,632 veterans with high blood pressure. Those ...
... that tuning out distractions can be learned , MONDAY, ... how a person,s brain is organized, says a U.S. study ... music training. , All the participants were between the ages ... more than 10 years experience as a band or orchestra ...
... some of these heart medications aren,t perfect , , MONDAY, ... to show that certain cholesterol drugs have their limits ... study presented Monday at the American Heart Association annual ... statin Crestor did not reduce deaths in older patients ...
Cached Medicine News:Health News:Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP 2Health News:Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP 3Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 2Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 3Health News:IdentiGEN's DNA TraceBack(R) Receives USDA Process Verified Program Approval 2Health News:IdentiGEN's DNA TraceBack(R) Receives USDA Process Verified Program Approval 3Health News:Large VA study finds seasonal differences in blood pressure 2Health News:Training, Experience Can Change How Brains Work 2Health News:Certain Cholesterol Drugs Show Their Limits 2Health News:Certain Cholesterol Drugs Show Their Limits 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: